Market Intelligence, Clinical Progress, and High-Purity Reagents for Transcription Factor-Directed Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TCF4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TCF4 bHLH & Full-Length Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 expressed. |
View TCF4 Products |
| Gene Delivery | TCF4 Promise-ORF / Lentivirus Full-length ORF for stable reporter cell lines. |
View TCF4 Products |
| Benchmark Ab | Anti-TCF4 Benchmark Antibody (Reference Clone Sequence) Recombinant positive control for western blot and IP. |
View TCF4 Products |
| Validator | TCF4 siRNA Set For knockdown verification and specificity controls. |
View TCF4 Products |
| Mutant Panel | TCF4 PTHS-Associated Mutants (e.g., p.R580X, p.R495X) Sequence-verified disease variants for mechanism studies. |
View TCF4 Products |
| Heterodimer Partner | TCF3 (E2A) Recombinant Protein Forms obligate heterodimers with TCF4. Critical for binding assays. |
View TCF3 Products |
| Negative Regulator | ID2 Recombinant Protein Inhibitor of DNA binding protein. Functional antagonist. |
View ID2 Products |
| Related Target: ASCL1 | ASCL1 Heterodimeric partner in neuronal and neuroendocrine transcriptional programs. |
View ASCL1 Products |
| Related Target: NEUROD1 | NEUROD1 Parallel bHLH lineage factor; defines alternate SCLC molecular subtypes. |
View NEUROD1 Products |
| Related Target: BRD4 | BRD4 Synergistic epigenetic regulator in pDC networks. |
View BRD4 Products |
| Related Target: BCL2 | BCL2 Downstream survival pathway node for combination therapy. |
View BCL2 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| bHLH domain folding & dimerization fidelity | Mammalian HEK293 expressed; Sequence Verified; >95% purity by SDS-PAGE |
| DNA-binding / EMSA validation | High-specificity full-length and truncated variants with Theoretical MW confirmation |
| Intracellular Protein Interaction Screening | Full-length and truncated TCF4 proteins available with >95% purity for PROTAC and SPR assays |
| Isoform Specificity & Off-target Effects | Sequence-verified exact isoforms; rigorously checked by mass spectrometry; ortholog/paralog panel available |
| Lack of Reliable Cellular Controls | Sequence-validated lentiviral overexpression particles and specific siRNA sets |
| False Positives in Degradation Assays | High-affinity benchmark antibodies to monitor precise target degradation |
| Disease Mutation Mechanism (Pitt-Hopkins Syndrome) | PTHS-specific truncating mutants (p.R580X, p.R495X) expressed in HEK293 for comparative binding studies |
| Nuclear Delivery in Primary Neurons | High-titer Lentivirus Premade Particles for efficient transduction of terminally differentiated cells |
| Heterodimerization Validation | TCF3 (E2A) partner protein available for co-immunoprecipitation and AlphaScreen assays |
Live TCF4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TCF4-targeted therapeutics is intensifying across multiple disease areas. TCF4 (also known as E2-2 or ITF2) is a member of the bHLH transcription factor family and is implicated in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Fuchs Endothelial Corneal Dystrophy (FECD), Pitt-Hopkins Syndrome (PTHS), and small cell lung cancer (SCLC). Key disease-associated mutations include a variant linked to symmetrical acral keratoderma (UniProt VAR_079726), and several PTHS-causing mutations (e.g., p.R580X) that lead to nuclear localization indistinguishable from wild-type (VAR_066839). The therapeutic landscape is bifurcating into rare genetic disease correction (PTHS via gene therapy/ASO) and oncology modulation (BPDCN/SCLC via PROTACs and small molecule PPI inhibitors). Emerging modalities include cell-penetrant peptide conjugates, targeted protein degradation (PROTACs), and isoform-selective transcriptional modulators. Next‑wave R&D focuses on isoform-selective modulation and CNS-penetrant delivery formats.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| ASO / RNAi | Preclinical biotech, Biogen-modeled startups | FECD, BPDCN, PTHS | Knockdown Validation (Need validated siRNA / Benchmark Abs) |
| PROTAC / Degrader | Emerging platforms | Hematological Malignancies (BPDCN) | Ternary Complex Assay (Need high-purity recombinant proteins) |
| Small Molecule PPI Inhibitors | Emerging biotech / Academia | Small Cell Lung Cancer, Solid Tumors | bHLH dimerization assay (Need high-purity TCF4 & partner proteins) |
| Molecular Glue / PROTAC | Preclinical innovators | Oncology | Intracellular stabilization assay (Need specific TCF4 variants) |
| Antisense / siRNA Therapeutics | CNS-focused biotech | PTHS, Schizophrenia | Knockdown validation (Need validated siRNA) |
| Gene Therapy | Rare disease programs, Academic Consortia | PTHS | Expression verification (Need ORF lentivirus for model construction) |
Functional Domains and Key Mutations
TCF4 contains a conserved basic helix-loop-helix (bHLH) domain (UniProt P15884) responsible for DNA binding and dimerization. Known disease-relevant mutations include:
- Symmetrical acral keratoderma associated: likely pathogenic variant (VAR_079726).
- PTHS mutations: e.g., VAR_066839 (nuclear localization pattern indistinguishable from wild-type) and VAR_078644 (also in PTHS).
TarMart provides bHLH domain recombinant proteins and PTHS truncation mutants (e.g., p.R580X, p.R495X) for functional and mechanistic studies.
Related Target Recommendations
For combination therapy and system biology exploration, the following related targets are strongly complementary:
- BRD4: Epigenetic regulator synergistic in pDC networks.
- BCL2: Key downstream anti-apoptotic protein in BPDCN.
- ASCL1 / NEUROD1: bHLH heterodimer partners in neuronal and SCLC subtypes.
- ID2: Negative regulator of bHLH transcription factors.
- TCF3 (E2A): Obligate heterodimerization partner for TCF4 binding assays.